Patent · US Active

B7-DC variants immunogenic compositions and methods of use thereof

US8153595B2 · kind B2 · utility

42Cited by
57References
53Claims
0Family size

Assignee

Inventor

Key dates

Filing dateJul 11, 2008
Grant dateApr 10, 2012
Priority date—
Expiry dateJul 11, 2028

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K38/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compositions and methods for costimulating T cells (i.e., increasing antigen-specific proliferation of T cells, enhancing cytokine production by T cells, stimulating differentiation ad effector functions of T cells and/or promoting T cell survival) are provided. Suitable compositions include variant B7-DC polypeptides, fragments and fusion proteins thereof. Variant B7-DC polypeptides have reduced binding affinity for the inhibitory PD-1 ligand and substantially retain the ability to costimulate T cells. Methods for using variant B7-DC polypeptides to stimulate immune responses in subjects in need thereof are provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.